Epcore Fl-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.

Kim M. Linton; Philip Thompson; Stefano Luminari; Carla Casulo; Poliana Patah; Lingmin Zeng; J. P. Mei; Neha Dixit; Daniela Hoehn; Emmanuel Bachy

doi:10.1200/JCO.2024.42.16_suppl.TPS7084

Epcore Fl-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.

Kim M. Linton
, Philip Thompson
, Stefano Luminari
, Carla Casulo
, Poliana Patah
, Lingmin Zeng
, J. P. Mei
, Neha Dixit
, Daniela Hoehn
, Emmanuel Bachy

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

69 Downloads (Pure)

Original language	English
Article number	PB2955
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	42
Issue number	16
DOIs	https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS7084
Publication status	Published - 1 Jun 2024
Event	American Society of Clinical Oncology (ASCO) Annual Meeting 2024 - McCormick Place, Chicago, United States Duration: 31 May 2024 → 4 Jun 2024 https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/scheduled-sessions

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2024.42.16_suppl.TPS7084

Linton et-al-2024-epcore-fl-2-phase-3-trial-of-epcoritamab-with-rituximab-and-lenalidomide-(r2)-vs-chemoimmunotherapy-or-r2-inFinal published version, 55.2 KB

https://library.ehaweb.org/eha/2024/eha2024-congress/421721/kim.linton.epcore.fl-2.phase.3.trial.of.epcoritamab.with.rituximab.and.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29170%2Amarker%3D5102

Cite this

Linton, K. M., Thompson, P., Luminari, S., Casulo, C., Patah, P., Zeng, L., Mei, J. P., Dixit, N., Hoehn, D., & Bachy, E. (2024). Epcore Fl-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma. Journal of Clinical Oncology, 42(16), Article PB2955. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS7084

@article{ed9729e2a874444d99c037891457f9dc,

title = "Epcore Fl-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.",

author = "Linton, \{Kim M.\} and Philip Thompson and Stefano Luminari and Carla Casulo and Poliana Patah and Lingmin Zeng and Mei, \{J. P.\} and Neha Dixit and Daniela Hoehn and Emmanuel Bachy",

year = "2024",

month = jun,

day = "1",

doi = "10.1200/JCO.2024.42.16\_suppl.TPS7084",

language = "English",

volume = "42",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "16",

note = " American Society of Clinical Oncology (ASCO) Annual Meeting 2024, 2024 ASCO Annual Meeting ; Conference date: 31-05-2024 Through 04-06-2024",

url = "https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/scheduled-sessions",

}

Linton, KM, Thompson, P, Luminari, S, Casulo, C, Patah, P, Zeng, L, Mei, JP, Dixit, N, Hoehn, D & Bachy, E 2024, 'Epcore Fl-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.', Journal of Clinical Oncology, vol. 42, no. 16, PB2955. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS7084

Epcore Fl-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma. / Linton, Kim M.; Thompson, Philip; Luminari, Stefano et al.
In: Journal of Clinical Oncology, Vol. 42, No. 16, PB2955, 01.06.2024.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Epcore Fl-2

T2 - American Society of Clinical Oncology (ASCO) Annual Meeting 2024

AU - Linton, Kim M.

AU - Thompson, Philip

AU - Luminari, Stefano

AU - Casulo, Carla

AU - Patah, Poliana

AU - Zeng, Lingmin

AU - Mei, J. P.

AU - Dixit, Neha

AU - Hoehn, Daniela

AU - Bachy, Emmanuel

PY - 2024/6/1

Y1 - 2024/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001275557406335&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1200/JCO.2024.42.16_suppl.TPS7084

DO - 10.1200/JCO.2024.42.16_suppl.TPS7084

M3 - Meeting Abstract

SN - 0732-183X

VL - 42

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

M1 - PB2955

Y2 - 31 May 2024 through 4 June 2024

ER -

Epcore Fl-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R<SUP>2</SUP>) vs chemoimmunotherapy or R<SUP>2</SUP> in previously untreated follicular lymphoma.

UN SDGs

Access to Document

Other files and links

Cite this